More than 2 out of 3 Medicare enrollees are thought to be obese or overweight based on their body mass index (BMI), an estimate of body fat based on height and weight
Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US, Journal of Comparable Effectiveness Research (2025) FDA approves weight management drug for patients aged 12 and older, FDA (2020) Generic drugs: Questions & answers, FDA (2021) Liraglutide injection (weight management), Cleveland Clinic (2025) Liraglutide, StatPearls (2024) Teva announces FDA approval and launch of generic Saxenda (liraglutide injection) first generic GLP-1 indicated for weight loss, Teva (2025) Top weight loss medications, Obesity Medicine Association (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
The authors concluded, "The findings of this systematic review and meta-analysis indicate that physicians should be concerned about the increased risk of the gallbladder or biliary disease associated with GLP-1 RA use, especially at the higher doses recommended for weight loss
It is important to stress that both GR and TrxR rely on the NADPH/NADP system for their activity, thus establishing a link between the nicotinamide and thiol redox systems (Jones and Sies, 2015)
